01 June 2002 00:09 [Source: ICIS news]
HOUSTON (CNI)--American Pharmaceutical Partners (APP) said Friday it has received market approval from the US Food and Drug Administration (FDA) for its milrinone lactate injection for treatment of patients with acute low-output heart failure.
APP's generic version of milrinone is said by the company to be the equivalent of Sanofi-Synthelabo's Primacor, which had 2001 sales of some $186m (Euro198m).
Los Angeles, California-based APP said it has begun marketing milrinone in 10, 20 and 50 ml vials.
APP said that with the addition of milrinone, it now has five cardiovascular products on the market. APP had total sales in 2001 of $192m.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|
Asian Chemical Connections